Biohaven Ltd. (NYSE:BHVN) is one of the best small-cap biotech stocks to buy according to analysts. William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth On November 11, 2025, William Blair kept its “Market Perform” rating. The investment firm sees the FDA’s Complete Response Letter (CRL) for Vyglxia as a key driver for pipeline reprioritization. The firm also cited the company’s projection of a 60% reduction in direct spend on non-priority assets. William Blair believ ...